{"id":534929,"date":"2021-03-22T20:04:01","date_gmt":"2021-03-22T20:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=534929"},"modified":"2021-03-22T20:04:01","modified_gmt":"2021-03-22T20:04:01","slug":"neurofibromatosis-2-pipeline-insight-2021","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neurofibromatosis-2-pipeline-insight-2021_534929.html","title":{"rendered":"Neurofibromatosis 2 Pipeline Insight 2021"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1616390087.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neurofibromatosis 2 Pipeline Insight 2021\" src=\"https:\/\/www.abnewswire.com\/uploads\/1616390087.png\" alt=\"Neurofibromatosis 2 Pipeline Insight 2021\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;<span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neurofibromatosis-2-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Neurofibromatosis 2 Pipeline<\/strong><\/a><\/span>&rdquo; report has been added to DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&#8220;Neurofibromatosis 2 Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis 2 market. A detailed picture of the Neurofibromatosis 2 pipeline landscape is provided, which includes the disease overview and Neurofibromatosis 2 treatment guidelines. The assessment part of the report embraces in-depth Neurofibromatosis 2 commercial assessment and clinical assessment of the Neurofibromatosis 2 pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibromatosis 2 collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample copy of Neurofibromatosis 2 Pipeline- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2 Pipeline: Geography Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Global<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas\/vestibular schwannomas).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Emerging Drug<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>REC-2282: Recursion Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Pipeline Development Activities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of Neurofibromatosis 2 with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neurofibromatosis 2 treatment.<\/li>\n<li>Neurofibromatosis 2 key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, immunotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neurofibromatosis 2 market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Report Scope<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Neurofibromatosis 2 report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neurofibromatosis 2 across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of detailed profiles of Neurofibromatosis 2 therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed Neurofibromatosis 2 research and development progress and trial details, results wherever available, are also included in the pipeline study.<\/li>\n<li>Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neurofibromatosis 2.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample copy of Neurofibromatosis 2 Pipeline- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Following is the table of content of Neurofibromatosis 2 Pipeline report<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Neurofibromatosis 2&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Neurofibromatosis 2&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Neurofibromatosis 2&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Neurofibromatosis 2 Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Neurofibromatosis 2 Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Neurofibromatosis 2 Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Neurofibromatosis 2&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Neurofibromatosis 2&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Neurofibromatosis 2&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Neurofibromatosis 2&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Neurofibromatosis 2&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Neurofibromatosis 2&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Neurofibromatosis 2.&nbsp;&nbsp;&nbsp;<\/li>\n<li>In the coming years, the Neurofibromatosis 2 market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.<\/li>\n<li>The companies and academics that are working to assess challenges and seek opportunities that could influence Neurofibromatosis 2 R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li>A detailed portfolio of major pharma players who are involved in fueling the Neurofibromatosis 2 treatment market. Several potential therapies for Neurofibromatosis 2 are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Neurofibromatosis 2 market size in the coming years.&nbsp;<\/li>\n<li>Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Neurofibromatosis 2) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis 2: Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for Neurofibromatosis 2 treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of Neurofibromatosis 2?<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of Neurofibromatosis 2?<\/li>\n<li>How many Neurofibromatosis 2 emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Neurofibromatosis 2?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Neurofibromatosis 2 market?<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of Neurofibromatosis 2?&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Neurofibromatosis 2 therapies?<\/li>\n<li>What are the clinical studies going on for Neurofibromatosis 2 and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for Neurofibromatosis 2?<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of Neurofibromatosis 2?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neurofibromatosis-2-market\" target=\"_blank\"><strong>Neurofibromatosis&nbsp;2&nbsp;Market<\/strong><\/a><\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neurofibromatosis-2-epidemiology-forecast\" target=\"_blank\"><strong>Neurofibromatosis&nbsp;2&nbsp;Epidemiology<\/strong><\/a><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57049.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Vinita Rakheja <br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neurofibromatosis-2-pipeline-insight-2021\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neurofibromatosis-2-pipeline-insight-2021\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; &ldquo;Neurofibromatosis 2 Pipeline&rdquo; report has been added to DelveInsight &nbsp; &#8220;Neurofibromatosis 2 Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis 2 market. A detailed picture of the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neurofibromatosis-2-pipeline-insight-2021_534929.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,413],"tags":[],"class_list":["post-534929","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=534929"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/534929\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=534929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=534929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=534929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}